- Free shipping on all orders over $200 (US) and $300 (International)
BPC-157 arginate (sold as “Pentadeca Arginate” or PDA) and BPC-157 acetate are the same 15-amino-acid peptide. The only difference is the counter-ion paired with it: arginine instead of acetate. When the FDA’s compounding advisory panel voted on BPC-157 in July 2026, it covered the free base and acetate forms only. The arginate form was not part of the vote.
Most synthetic peptides are not sold as a bare molecule. They carry positive charges on basic amino acids and on the N-terminus, and those charges pair with negatively charged counter-ions. The peptide plus its counter-ions is the salt form.
Three counter-ions show up most often:
The amino acid sequence does not change between salt forms. What changes is the non-peptide mass in the vial, and properties like solubility and stability in solution.
The peptide is identical. BPC-157 is the sequence GEPPPGKPADDAGLV in both forms. Our BPC-157 vs TB-500 guide covers its background.
| BPC-157 acetate | BPC-157 arginate (PDA) | |
|---|---|---|
| Peptide sequence | GEPPPGKPADDAGLV | GEPPPGKPADDAGLV |
| Counter-ion | Acetate | Arginine |
| How common | Standard form from most suppliers | Niche; mostly marketed as “Pentadeca Arginate” |
| Named in the July 2026 FDA panel vote | Yes | No |
| Stability claims | Typical for an acetate peptide salt | Marketed as more stable in acidic conditions; no independent data we could find |
| Non-peptide mass per molecule | Lower | Higher (arginine is heavier than acetate) |
The PDA name rose after the FDA placed BPC-157 in Category 2 in September 2023. Some sellers argued the arginate salt was a separate substance not covered by that listing. As of April 2026, the FDA had not issued any guidance treating PDA as distinct from BPC-157. Because the sequence is the same, any research claim made for PDA rests on the existing BPC-157 literature.
On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee voted 8 to 6, with 1 abstention, to recommend adding BPC-157 to the 503A bulks list. The recommendation named two forms: BPC-157 free base and BPC-157 acetate. The arginate salt was not reviewed.
What that means in practice:
The same day, the panel also backed KPV and TB-500, two peptides that sit alongside BPC-157 in the KLOW and GLOW blends.
Counter-ions add weight that is not peptide. Arginine weighs about 174 g/mol, roughly three times more than acetate at about 59 g/mol. So for every counter-ion attached, an arginate salt carries more non-peptide mass than an acetate salt.
That makes one question important when you compare two vials labeled “10 mg”: is that 10 mg of peptide, or 10 mg of salt? The answer is on the COA, as net peptide content. Two vials can both show 99% purity and still hold different amounts of actual BPC-157.
We break this down with a worked example in peptide purity vs net peptide content, and our COA reading guide shows where to find the salt form on the report.
Yes, in sequence. Pentadeca Arginate (PDA) is BPC-157 paired with an arginine counter-ion instead of acetate. The 15 amino acids are identical.
It is marketed that way, mainly for acidic conditions. We have not found independent, peer-reviewed data comparing the two salts directly, so treat the claim as unverified.
The free base and acetate forms, by an 8-6 vote with 1 abstention on July 23, 2026. The arginate form was not reviewed.
No. The panel’s vote is a non-binding recommendation about compounding. BPC-157 is not an FDA-approved drug in any salt form.
It describes the peptide without a specified counter-ion. In practice, most commercial BPC-157 is supplied as a salt, and the COA should say which one.
Yes. A complete COA names the salt form and states net peptide content, so you know how much of the weighed powder is the peptide itself.
